Incidence and predictors of worsening heart failure in patients with wild‐type transthyretin cardiac amyloidosis

Background Prognostic markers of survival have been identified in wild‐type transthyretin amyloidosis (ATTRwt), but limited data exist with respect to hospitalizations with worsening heart failure (WHF). Predictive markers of WHF have yet to be identified. Methods From April 2017 to February 2021, 1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESC Heart Failure 2022-10, Vol.9 (5), p.2978-2987
Hauptverfasser: Ladefoged, Bertil Thyrsted, Dybro, Anne, Dahl Pedersen, Anders Lehmann, Rasmussen, Torsten Bloch, Vase, Henrik Ølholm, Clemmensen, Tor Skibsted, Gillmore, Julian, Poulsen, Steen Hvitfeldt
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Prognostic markers of survival have been identified in wild‐type transthyretin amyloidosis (ATTRwt), but limited data exist with respect to hospitalizations with worsening heart failure (WHF). Predictive markers of WHF have yet to be identified. Methods From April 2017 to February 2021, 104 patients with ATTRwt were diagnosed and prospectively followed from the time of diagnosis to the time of death or the censoring date of 1 February 2021. Baseline patient characteristics, biomarkers, and advanced echocardiography were used to predict hospitalization with WHF. Results During the median follow‐up period of 23 months, 51% of patients were hospitalized due to WHF. Seventy‐three per cent of patients with WHF were admitted at least twice. Patients with WHF during the first year had significantly poorer survival (P 
ISSN:2055-5822
2055-5822
DOI:10.1002/ehf2.14000